Insights from 2023 ASCO® Annual Meeting
Initial Efficacy & Safety Results From a Phase 2 ENGOT-ov60/GOG-3052/RAMP 201 Study: Avutometinib (VS-6766) ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Susana Banerjee
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Susana Banerjee
Comments 0
Login to view comments.
Click here to Login
